533 related articles for article (PubMed ID: 20172966)
1. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.
Ban K; Kim KH; Cho CK; Sauvé M; Diamandis EP; Backx PH; Drucker DJ; Husain M
Endocrinology; 2010 Apr; 151(4):1520-31. PubMed ID: 20172966
[TBL] [Abstract][Full Text] [Related]
2. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
Ban K; Noyan-Ashraf MH; Hoefer J; Bolz SS; Drucker DJ; Husain M
Circulation; 2008 May; 117(18):2340-50. PubMed ID: 18427132
[TBL] [Abstract][Full Text] [Related]
3. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
4. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.
Oeseburg H; de Boer RA; Buikema H; van der Harst P; van Gilst WH; Silljé HH
Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1407-14. PubMed ID: 20448207
[TBL] [Abstract][Full Text] [Related]
6. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
Göke R; Fehmann HC; Linn T; Schmidt H; Krause M; Eng J; Göke B
J Biol Chem; 1993 Sep; 268(26):19650-5. PubMed ID: 8396143
[TBL] [Abstract][Full Text] [Related]
7. Antidiabetic drug voglibose is protective against ischemia-reperfusion injury through glucagon-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway in rabbits.
Iwasa M; Kobayashi H; Yasuda S; Kawamura I; Sumi S; Yamada Y; Shiraki T; Yamaki T; Ushikoshi H; Aoyama T; Nishigaki K; Takemura G; Fujiwara T; Fujiwara H; Minatoguchi S
J Cardiovasc Pharmacol; 2010 Jun; 55(6):625-34. PubMed ID: 20351564
[TBL] [Abstract][Full Text] [Related]
8. Exendin-4 ameliorates renal ischemia-reperfusion injury in the rat.
Yang H; Li H; Wang Z; Shi Y; Jiang G; Zeng F
J Surg Res; 2013 Dec; 185(2):825-32. PubMed ID: 23890403
[TBL] [Abstract][Full Text] [Related]
9. Receptor identification and physiological characterisation of glucagon-like peptide-2 in the rat heart.
Angelone T; Filice E; Quintieri AM; Imbrogno S; Amodio N; Pasqua T; Pellegrino D; Mulè F; Cerra MC
Nutr Metab Cardiovasc Dis; 2012 Jun; 22(6):486-94. PubMed ID: 21186112
[TBL] [Abstract][Full Text] [Related]
10. Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat.
Bao W; Holt LJ; Prince RD; Jones GX; Aravindhan K; Szapacs M; Barbour AM; Jolivette LJ; Lepore JJ; Willette RN; DeAngelis E; Jucker BM
Cardiovasc Diabetol; 2013 Oct; 12():148. PubMed ID: 24125539
[TBL] [Abstract][Full Text] [Related]
11. Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39).
Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Metabolism; 2004 Feb; 53(2):252-9. PubMed ID: 14767880
[TBL] [Abstract][Full Text] [Related]
12. Postconditioning with curaglutide, a novel GLP-1 analog, protects against heart ischemia-reperfusion injury in an isolated rat heart.
Salling HK; Döhler KD; Engstrøm T; Treiman M
Regul Pept; 2012 Oct; 178(1-3):51-5. PubMed ID: 22749991
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.
Gupta NA; Mells J; Dunham RM; Grakoui A; Handy J; Saxena NK; Anania FA
Hepatology; 2010 May; 51(5):1584-92. PubMed ID: 20225248
[TBL] [Abstract][Full Text] [Related]
14. Evidence for paracrine/autocrine regulation of GLP-1-producing cells.
Kappe C; Zhang Q; Holst JJ; Nyström T; Sjöholm A
Am J Physiol Cell Physiol; 2013 Nov; 305(10):C1041-9. PubMed ID: 23986202
[TBL] [Abstract][Full Text] [Related]
15. Allosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptor.
Li N; Lu J; Willars GB
PLoS One; 2012; 7(10):e47936. PubMed ID: 23094100
[TBL] [Abstract][Full Text] [Related]
16. Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39).
Fehmann HC; Jiang J; Schweinfurth J; Wheeler MB; Boyd AE; Göke B
Peptides; 1994; 15(3):453-6. PubMed ID: 7937318
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
Liu L; Liu J; Wong WT; Tian XY; Lau CW; Wang YX; Xu G; Pu Y; Zhu Z; Xu A; Lam KS; Chen ZY; Ng CF; Yao X; Huang Y
Hypertension; 2012 Sep; 60(3):833-41. PubMed ID: 22868389
[TBL] [Abstract][Full Text] [Related]
18. Functional activity of murine intestinal mucosal cells is regulated by the glucagon-like peptide-1 receptor.
Kedees MH; Guz Y; Grigoryan M; Teitelman G
Peptides; 2013 Oct; 48():36-44. PubMed ID: 23927844
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells.
Koehler JA; Kain T; Drucker DJ
Endocrinology; 2011 Sep; 152(9):3362-72. PubMed ID: 21771884
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis.
Marzioni M; Alpini G; Saccomanno S; Candelaresi C; Venter J; Rychlicki C; Fava G; Francis H; Trozzi L; Glaser S; Benedetti A
Gastroenterology; 2007 Jul; 133(1):244-55. PubMed ID: 17631146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
